Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.
Saved in:
| Title: | Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. |
|---|---|
| Authors: | Grivas P; Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle, WA, 98109, USA. pgrivas@uw.edu., Monk BJ; Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA., Petrylak D; Department of Urology, Yale University School of Medicine, New Haven, CT, USA., Reck M; Department of Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Lung Clinic Grosshansdorf, Grosshansdorf, Germany., Foley G; Pfizer Ltd., Tadworth, UK., Guenther S; Merck KGaA, Darmstadt, Germany., Hennessy D; EMD Serono, Rockland, MA, USA., Makris C; Pfizer Inc., New York, NY, USA., Moehler M; Johannes-Gutenberg University, University Medical Center, Mainz, Germany. |
| Source: | Targeted oncology [Target Oncol] 2019 Oct; Vol. 14 (5), pp. 505-525. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1776-260X |
|---|---|
| DOI: | 10.1007/s11523-019-00665-1 |
